Lambert-Eaton Myasthenic Syndrome (LEMS)

1. Clinical Overview

Summary

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction characterized by proximal muscle weakness, autonomic dysfunction, and reduced or absent tendon reflexes. The condition is caused by IgG antibodies against presynaptic voltage-gated calcium channels (VGCCs), predominantly the P/Q-type, which impair acetylcholine (ACh) release from motor nerve terminals. [1,2]

The hallmark clinical triad consists of:

1. Proximal weakness (predominantly lower limbs)
2. Autonomic dysfunction (dry mouth most common)
3. Areflexia or hyporeflexia with post-tetanic potentiation (transient improvement after brief exercise)

LEMS is strongly associated with malignancy, particularly Small Cell Lung Cancer (SCLC). Approximately 50-60% of cases are paraneoplastic, with SCLC accounting for over 95% of cancer-associated LEMS. [3,4] Neurological symptoms may precede cancer diagnosis by months to years, making LEMS an important oncological red flag. The remaining 40-50% are autoimmune (non-paraneoplastic) and often occur in younger patients with other autoimmune conditions. [5]

Diagnosis relies on clinical features, anti-P/Q-type VGCC antibodies (positive in 85-90%), and characteristic electrophysiological findings on repetitive nerve stimulation (RNS) showing an incremental response (> 100% increase in compound muscle action potential amplitude at high-frequency stimulation or post-exercise). [6,7]

Treatment encompasses cancer management (in paraneoplastic cases), symptomatic therapy with 3,4-diaminopyridine (3,4-DAP), and immunotherapy (IVIG, corticosteroids, steroid-sparing agents). With appropriate treatment, functional improvement is achievable in most patients. [8,9]

Clinical Pearls

"Weakness that Gets Better with Exercise": Unlike myasthenia gravis where weakness worsens with repetitive activity (fatigability), LEMS may show transient improvement after brief exertion due to post-tetanic potentiation.

"LEMS = Look for Lung Cancer": The association with SCLC is critical. All patients require comprehensive cancer screening with CT chest as a minimum, and PET-CT if initial imaging is negative but clinical suspicion remains high.

"Proximal > Distal, Legs > Arms": Difficulty rising from a chair or climbing stairs is typical. Lower limb proximal weakness predominates early in the disease course.

"Dry Mouth is the Clue": Autonomic features, especially xerostomia (dry mouth), occur in ~80% of patients and may be the presenting symptom.

"Incremental Response on EMG": The diagnostic hallmark is an incremental response on high-frequency RNS (opposite to the decremental response in myasthenia gravis).

---

2. Epidemiology

Incidence and Prevalence

Lambert-Eaton Myasthenic Syndrome is a rare condition with an estimated incidence of 0.5-1.0 per million population per year. [10] Prevalence estimates range from 2.5-3.0 per million, making it significantly less common than myasthenia gravis (prevalence 150-250 per million). [11,12]

Demographics

Age Distribution

LEMS exhibits a bimodal age distribution:

• Autoimmune LEMS: Peak onset 35-40 years
• Paraneoplastic LEMS: Peak onset 55-65 years (reflecting SCLC demographics) [13]

The older age group association reflects the typical age of SCLC diagnosis. Pediatric cases are extremely rare but have been reported. [14]

Sex Distribution

Overall, LEMS shows a slight male predominance (male:female ratio approximately 1.5-2:1), primarily driven by the paraneoplastic subset where males are significantly more affected due to higher SCLC rates. [15]

In contrast, autoimmune LEMS shows equal sex distribution or slight female predominance, consistent with other autoimmune disorders. [5]

Geographic and Ethnic Variation

Limited data exist on ethnic variations. LEMS has been reported across all ethnic groups, though most published series are from predominantly Caucasian populations in Europe and North America. [16]

Risk Factors

Paraneoplastic LEMS

Autoimmune LEMS

---

3. Aetiology and Pathophysiology

Etiology

LEMS can be divided into two distinct etiological categories:

Paraneoplastic LEMS (50-60% of cases)

The vast majority of paraneoplastic LEMS is associated with Small Cell Lung Cancer (SCLC), accounting for > 95% of cancer-associated cases. [3,4] Other rare malignancies have been reported, including:

• Non-small cell lung cancer
• Lymphoproliferative disorders
• Thymoma
• Prostate cancer

Pathogenesis: SCLC cells express neuronal antigens including P/Q-type voltage-gated calcium channels on their surface. The immune response mounted against the tumor cross-reacts with identical channels at the neuromuscular junction, resulting in an antibody-mediated neuromuscular transmission disorder. [22]

Clinical Significance:

• LEMS may precede cancer diagnosis by months to years (median 3-5 months, range up to 2-3 years) [23]
• Approximately 3% of SCLC patients develop LEMS [18]
• Earlier cancer detection in LEMS patients is associated with better oncological outcomes [24]

Non-Paraneoplastic (Autoimmune) LEMS (40-50% of cases)

In the absence of malignancy, LEMS is a primary autoimmune disorder. These patients are often younger and may have:

• Other organ-specific autoimmune diseases (thyroid disease in ~15-20%, vitiligo, pernicious anemia) [5]
• HLA-B8 association [20]
• Chronic relapsing-remitting course

Molecular Pathophysiology

Normal Neuromuscular Transmission

Understanding LEMS requires knowledge of normal neuromuscular junction physiology:

1. Action potential arrives at presynaptic motor nerve terminal
2. Voltage-gated calcium channels (VGCCs) open in response to depolarization
3. Calcium influx (Ca²⁺) into the nerve terminal
4. Calcium-dependent fusion of acetylcholine-containing vesicles with presynaptic membrane
5. Acetylcholine (ACh) release into synaptic cleft
6. ACh binds to nicotinic receptors on postsynaptic muscle membrane
7. Endplate potential exceeds threshold, triggering muscle action potential and contraction

LEMS Pathophysiology

The autoimmune attack in LEMS targets the presynaptic terminal:

Step 1: Antibody Production

• IgG autoantibodies against P/Q-type voltage-gated calcium channels (VGCCs)
• Antibodies bind to the α1A subunit of the Cav2.1 channel [1,2]
• Additional antibodies may target N-type VGCCs and other synaptic proteins (synaptotagmin, VAMP) [25]

Step 2: VGCC Internalization and Destruction

• Antibody binding triggers complement-mediated lysis and receptor cross-linking
• Endocytosis of antibody-VGCC complexes
• Reduction in functional VGCC density by 50-90% at active zones [26]
• Disruption of active zone architecture

Step 3: Impaired Calcium Influx

• Fewer functional calcium channels → reduced Ca²⁺ entry per action potential
• Insufficient calcium to trigger normal quantal ACh release

Step 4: Reduced Acetylcholine Release

• Decreased number of ACh vesicles released (reduced quantal content)
• Normal single quantum size (unlike myasthenia gravis where postsynaptic response is impaired)

Step 5: Neuromuscular Transmission Failure

• Insufficient ACh to generate endplate potentials that reliably reach threshold
• Muscle weakness results from failed neuromuscular transmission

Post-Tetanic Potentiation: The Diagnostic Clue

One of the most distinctive features of LEMS is post-tetanic potentiation (also called post-exercise facilitation):

Mechanism:

• With high-frequency stimulation or sustained muscle contraction, action potentials occur in rapid succession
• Calcium accumulates in the presynaptic terminal (residual calcium from previous action potentials persists)
• This accumulated calcium temporarily compensates for the reduced number of VGCCs
• Increased ACh release for a brief period (10-60 seconds)
• Transient improvement in strength and reflexes

Clinical Manifestation:

• Absent ankle reflexes may transiently appear after 10 seconds of sustained plantar flexion (Lambert's sign)
• Hand grip strength may improve after brief repeated contractions
• This is opposite to myasthenia gravis where weakness worsens with repetitive activity

Autonomic Dysfunction

P/Q-type VGCCs are also present at autonomic nerve terminals (sympathetic and parasympathetic), explaining the prominent autonomic features in LEMS:

Affected Systems:

• Salivary glands: Reduced secretion → dry mouth (xerostomia) - most common, ~80% [27]
• Gastrointestinal: Reduced motility → constipation
• Cardiovascular: Postural hypotension, impaired heart rate variability
• Genitourinary: Erectile dysfunction in males, bladder dysfunction
• Ocular: Impaired pupillary constriction, dry eyes

Comparison: LEMS vs Myasthenia Gravis

Understanding the differences is critical for diagnosis and exam purposes:

---

4. Clinical Presentation

Motor Symptoms and Signs

Proximal Muscle Weakness

The cardinal motor feature of LEMS is proximal muscle weakness, predominantly affecting the lower limbs.

Typical Presentation:

Examination Findings:

• MRC grading: Typically 3-4/5 in proximal muscles (hip flexors, shoulder abductors)
• Distal strength: Relatively preserved initially
• Symmetrical involvement
• Progressive if untreated

Reduced or Absent Reflexes (Areflexia/Hyporeflexia)

Deep tendon reflexes are characteristically reduced or absent in LEMS, particularly in the lower limbs. [6]

Lambert's Sign (Post-Tetanic Potentiation):

• Method: Test ankle reflexes → absent. Then ask patient to perform sustained plantar flexion for 10-15 seconds → immediately re-test ankle reflexes
• Positive result: Reflexes transiently appear or become brisker
• Duration: Improvement lasts 10-60 seconds before reflexes disappear again
• Sensitivity: ~40-50% (not always demonstrable) [29]

This phenomenon is pathognomonic for LEMS and reflects the underlying presynaptic defect with post-tetanic facilitation.

Cranial Nerve Involvement

Unlike myasthenia gravis, bulbar and ocular symptoms are less prominent in LEMS:

Clinical Pearl: If a patient presents with prominent ptosis and diplopia, think myasthenia gravis first. If proximal leg weakness and dry mouth predominate, think LEMS.

Respiratory Muscle Involvement

Respiratory failure is rare in LEMS (less than 5%) but can occur in severe cases. [31] Risk factors include:

• Severe disease with marked generalized weakness
• Coexisting SCLC with bulky thoracic disease
• Intercurrent illness (pneumonia)

Autonomic Symptoms

Autonomic dysfunction is a hallmark feature of LEMS and often provides the diagnostic clue.

Diagnostic Value: The combination of proximal weakness + dry mouth + reduced reflexes should immediately raise suspicion for LEMS.

Cancer-Associated Symptoms

In paraneoplastic LEMS, patients may have symptoms related to SCLC:

Constitutional Symptoms

Clinical Vignette (Typical Presentation)

Case: A 58-year-old male smoker presents with a 3-month history of difficulty climbing stairs and rising from chairs. He reports troublesome dry mouth and constipation. On examination, there is 4/5 proximal weakness in the lower limbs, and ankle reflexes are absent but transiently appear after sustained plantar flexion. Diplopia and ptosis are absent.

Diagnosis: LEMS with high probability of paraneoplastic etiology (age, smoking, sex) → urgent cancer screening required.

---

5. Investigations

Diagnostic Pathway

SUSPECTED LEMS
(Proximal weakness + autonomic features + reduced reflexes ± post-tetanic potentiation)
                    ↓
┌───────────────────────────────────────────────────────┐
│  CONFIRMATORY TESTS                                   │
│  1. Serology: Anti-VGCC antibodies (P/Q-type)        │
│  2. Electrophysiology: Repetitive Nerve Stimulation  │
│  3. Consider: Single fiber EMG if RNS equivocal      │
└───────────────────────────────────────────────────────┘
                    ↓
           DIAGNOSIS CONFIRMED
                    ↓
┌───────────────────────────────────────────────────────┐
│  CANCER SCREENING (MANDATORY)                         │
│  - All patients require malignancy workup             │
└───────────────────────────────────────────────────────┘

Serological Tests

Anti-Voltage-Gated Calcium Channel (VGCC) Antibodies

Gold Standard Diagnostic Test:

• Target: P/Q-type VGCC α1A subunit (Cav2.1)
• Sensitivity: 85-90% for LEMS [6,7]
• Specificity: 95-99% (rarely positive in other conditions)

Interpretation:

• Positive: Confirms LEMS diagnosis
• Negative: Does not exclude LEMS; 10-15% of clinical LEMS are seronegative [32]
• Quantitative titers: Do not correlate well with disease severity (qualitative test sufficient)

Assay Method: Radioimmunoprecipitation assay (most sensitive)

Additional Antibodies to Test:

• Anti-N-type VGCC: Present in ~30% of LEMS patients [25]
• Anti-synaptotagmin: Associated with LEMS, less specific
• Anti-SOX1: See below

Anti-SOX1 Antibodies

Clinical Significance: Marker for paraneoplastic etiology (SCLC association)

• Frequency: Positive in 40-60% of paraneoplastic LEMS [19]
• Specificity: Highly specific for paraneoplastic etiology (> 95%)
• Negative test: Does not exclude SCLC; sensitivity only 40-60%

Clinical Use:

• If SOX1-positive → very high probability of SCLC → aggressive cancer screening
• If SOX1-negative → still perform cancer screening (not sensitive enough to exclude)

Acetylcholine Receptor (AChR) Antibodies

• Should be negative in LEMS
• Test to exclude myasthenia gravis in the differential diagnosis
• Rarely, patients can have overlap syndrome (LEMS + MG) with both VGCC and AChR antibodies [33]

Electrophysiology

Electrophysiological testing is essential for diagnosis and provides the characteristic pattern that distinguishes LEMS from other neuromuscular disorders.

Repetitive Nerve Stimulation (RNS)

The Diagnostic Hallmark of LEMS

Technique:

1. Surface electrodes placed over muscle (often abductor digiti minimi or trapezius)
2. Nerve stimulated supramaximally
3. Compound Muscle Action Potential (CMAP) recorded

RNS Protocol:

A. Resting CMAP Amplitude:

• Often reduced (50-70% of normal) at rest [34]

B. Low-Frequency Stimulation (2-3 Hz):

• Decremental response (similar to myasthenia gravis)
• CMAP amplitude decreases by > 10%

C. High-Frequency Stimulation (20-50 Hz) or Post-Exercise Facilitation:

• INCREMENTAL RESPONSE (diagnostic for LEMS)
• CMAP amplitude increases by > 100% (often 200-400%) [6,7]
• This reflects post-tetanic potentiation

Diagnostic Criteria:

• Incremental response ≥100% after high-frequency stimulation or 10-15 seconds of maximal voluntary contraction
• This is pathognomonic for LEMS

Example:

• Resting CMAP: 2 mV (reduced; normal ~10 mV)
• After high-frequency stimulation: 6 mV
• Increment: 200% → diagnostic of LEMS

Sensitivity: ~90-95% when both low- and high-frequency RNS are performed [34]

Single Fiber Electromyography (SF-EMG)

Findings:

• Increased jitter (abnormal variability in neuromuscular transmission)
• Blocking (some potentials fail to fire)

Clinical Use:

• Highly sensitive (> 95%) but non-specific (also abnormal in MG, neuropathies)
• Used when RNS is equivocal or negative
• Not routinely required if RNS is diagnostic

Cancer Screening

MANDATORY in all LEMS patients due to 50-60% paraneoplastic association.

Initial Screening (All Patients)

If Initial Screening Negative

PET-CT Whole Body:

• Indication: Initial CT chest negative but high clinical suspicion (SOX1-positive, age > 50, smoker, weight loss)
• Sensitivity: Higher than CT alone (~95%) for detecting small/occult malignancies [36]
• Detection: May identify SCLC not visible on CT, or extrathoracic malignancies

Ongoing Surveillance

If initial comprehensive screening is negative:

Repeat imaging protocol [37]:

• Every 6 months for 2 years
• Then annually for up to 5 years
• Modality: CT chest (alternating with PET-CT if high risk)

Rationale: In ~10% of cases, SCLC may emerge months to years after LEMS diagnosis. [23,24]

DELTA-P Score: Predicting Paraneoplastic LEMS

A clinical tool to estimate probability of SCLC in LEMS patients:

Interpretation:

• Score ≥3: High probability of SCLC → aggressive screening with PET-CT
• Score less than 3: Lower probability but still requires CT chest surveillance

Validation: Sensitivity 89%, specificity 79% for SCLC [38]

Other Investigations

Baseline Blood Tests

Edrophonium (Tensilon) Test

Rarely used in modern practice:

• Response: Variable/minimal in LEMS (compared to dramatic improvement in MG)
• Reason: Defect is presynaptic (reduced ACh release), so increasing ACh availability has limited effect
• Clinical utility: Low; serological and electrophysiological tests are superior

---

6. Differential Diagnosis

Key Differentials

Clinical Clues to Diagnosis

Think LEMS if:

• Proximal weakness + dry mouth + reduced reflexes
• Post-tetanic potentiation (Lambert's sign)
• Age > 50 with smoking history (paraneoplastic)
• Incremental response on RNS

Think Myasthenia Gravis if:

• Ptosis and diplopia prominent
• Fatigability with repetitive activity
• Normal reflexes
• Decremental response on RNS

---

7. Management

Treatment Principles

LEMS management has three pillars:

1. Cancer Treatment (if paraneoplastic)
2. Symptomatic Treatment (3,4-DAP to enhance ACh release)
3. Immunotherapy (reduce antibody production)

Management Algorithm

                  CONFIRMED LEMS DIAGNOSIS
                  (Anti-VGCC + RNS incremental response)
                            ↓
                 CANCER SCREENING (Mandatory)
                            ↓
        ┌───────────────────┴────────────────────┐
        ↓                                        ↓
PARANEOPLASTIC LEMS                    NON-PARANEOPLASTIC LEMS
(SCLC or other cancer)                 (Autoimmune)
        ↓                                        ↓
┌───────────────────┐                  ┌─────────────────────┐
│ TREAT CANCER      │                  │ IMMUNOTHERAPY       │
│ (Priority)        │                  │ (Mainstay)          │
│ - Chemotherapy    │                  │ - IVIG              │
│ - Radiotherapy    │                  │ - Prednisolone      │
│ - Surgery (rare)  │                  │ - Azathioprine      │
│                   │                  │ - Mycophenolate     │
│ Cancer treatment  │                  │ - Rituximab         │
│ often improves    │                  │   (refractory)      │
│ LEMS symptoms     │                  │                     │
└─────────┬─────────┘                  └──────────┬──────────┘
          │                                       │
          └────────────────┬──────────────────────┘
                           ↓
           ┌───────────────────────────────────────┐
           │ SYMPTOMATIC TREATMENT (ALL PATIENTS)  │
           │                                       │
           │ 3,4-DIAMINOPYRIDINE (Amifampridine)  │
           │ - First-line symptomatic agent        │
           │ - Dose: 10-20 mg TDS-QDS             │
           │ - Max: 80 mg/day                     │
           │ - Monitor: Seizure risk at high dose │
           │                                       │
           │ PYRIDOSTIGMINE (Adjunct)             │
           │ - Modest benefit                      │
           │ - Dose: 30-60 mg TDS-QDS             │
           └───────────────────────────────────────┘
                           ↓
                SUPPORTIVE MEASURES
         - Avoid drugs impairing NMJ transmission
         - Physiotherapy and OT
         - Fall prevention
         - MDT approach

Symptomatic Treatment

3,4-Diaminopyridine (Amifampridine)

First-line symptomatic agent for LEMS [8,9]

Mechanism of Action:

• Blocks voltage-gated potassium (K⁺) channels on presynaptic nerve terminal
• Prolongs depolarization of nerve terminal
• Allows more time for calcium influx through remaining VGCCs
• Increases acetylcholine release

Efficacy:

• Cochrane review: Significant improvement in muscle strength and autonomic symptoms [8]
• Effect size: ~30% improvement in limb strength scores
• Onset of action: Days to 1-2 weeks
• Benefit maintained long-term

Dosing:

• Starting dose: 10 mg three times daily (TDS)
• Maintenance: 15-20 mg TDS-QDS (three to four times daily)
• Maximum: 80 mg/day (divided doses)
• Take on empty stomach (better absorption)

Side Effects:

Contraindications:

• Epilepsy or seizure history (relative contraindication)
• Uncontrolled asthma (bronchospasm risk)

Monitoring:

• Baseline: ECG (QT interval - rare prolongation)
• Follow-up: Clinical response, side effects
• EEG: Not routinely required unless seizure history

Availability:

• Licensed in UK (Firdapse), EU, USA
• Available through named-patient programs in some countries

Pyridostigmine

Acetylcholinesterase inhibitor (same as used in myasthenia gravis)

Mechanism:

• Inhibits breakdown of ACh in synaptic cleft
• Increases ACh availability for postsynaptic receptors

Efficacy in LEMS:

• Modest benefit compared to MG (presynaptic defect means less ACh released in the first place)
• Often used as adjunct to 3,4-DAP
• Some patients derive benefit

Dosing:

• 30-60 mg QDS (four times daily)
• Maximum: 120 mg QDS

Side Effects:

• Cholinergic: Abdominal cramps, diarrhea, hypersalivation, sweating

Immunotherapy

Paraneoplastic LEMS

Cancer treatment is the priority and often leads to improvement in LEMS symptoms. [24]

Chemotherapy for SCLC:

• Platinum-based regimens (cisplatin/carboplatin + etoposide)
• Improvement in LEMS occurs in ~50% of patients after chemotherapy [40]
• Mechanism: Reduction in tumor burden → reduced antigen load → reduced antibody production

Adjunct Immunotherapy (while cancer treatment ongoing):

• IVIG or plasma exchange for severe weakness
• Corticosteroids: Use with caution (may impair cancer treatment efficacy)

Non-Paraneoplastic (Autoimmune) LEMS

Immunotherapy is the mainstay of treatment.

A. Intravenous Immunoglobulin (IVIG)

Indication: First-line for acute exacerbations or rapidly progressive weakness

Mechanism:

• Antibody neutralization
• Modulation of immune system

Dosing:

• 2 g/kg divided over 2-5 days (e.g., 0.4 g/kg/day for 5 days)

Efficacy:

• Improvement in 60-70% of patients [41]
• Onset: 1-2 weeks
• Duration: 4-8 weeks (repeated courses often needed)

Side Effects:

• Headache, fever (common)
• Aseptic meningitis (rare)
• Thromboembolism (rare, especially if immobile or hypercoagulable)
• Renal impairment (pre-hydration recommended)

B. Corticosteroids

Indication: Long-term immunosuppression in autoimmune LEMS

Regimen:

• Prednisolone 0.5-1 mg/kg/day (typically 40-60 mg)
• Taper slowly once response achieved (over months)
• Maintain on lowest effective dose

Efficacy:

• Improvement in 60-80% of patients
• Onset: 2-4 weeks (slower than IVIG)

Side Effects:

• Osteoporosis prevention: Bisphosphonates, calcium, vitamin D
• Glucose monitoring (steroid-induced diabetes)
• Gastric protection (PPI)
• Infection risk

C. Steroid-Sparing Agents (Long-term Maintenance)

Azathioprine:

• Dose: 2-3 mg/kg/day (typically 100-150 mg)
• Onset: 3-6 months (slow)
• Monitoring: FBC, LFTs (weekly for 4 weeks, then monthly)
• TPMT testing: Before starting (risk of myelosuppression if deficient)

Mycophenolate Mofetil:

• Dose: 500-1000 mg BD
• Onset: 2-4 months
• Monitoring: FBC (leukopenia risk)
• Side effects: GI upset, infection risk

Methotrexate:

• Less commonly used in LEMS
• Dose: 10-25 mg weekly with folic acid

D. Rituximab

Indication: Refractory LEMS not responding to conventional immunotherapy

Mechanism: Anti-CD20 monoclonal antibody → B-cell depletion

Regimen:

• 1000 mg IV at weeks 0 and 2, or
• 375 mg/m² weekly for 4 weeks

Efficacy:

• Case series show improvement in 50-70% of refractory cases [42]
• Duration of effect: 6-12 months (may require repeat cycles)

Monitoring:

• B-cell counts
• Immunoglobulin levels (risk of hypogammaglobulinemia)
• Infection risk (PCP prophylaxis if required)

E. Plasma Exchange (Plasmapheresis)

Indication: Severe, acute LEMS with respiratory or bulbar compromise (rare)

Efficacy:

• Rapid improvement (within days)
• Short duration (2-4 weeks)

Regimen:

• 5 exchanges over 1-2 weeks

Use: Crisis management, followed by long-term immunotherapy

Supportive and Multidisciplinary Management

Physiotherapy and Occupational Therapy

• Strengthening exercises: Maintain muscle function
• Gait aids: Walking stick, frame, wheelchair if severe
• Home modifications: Rails, stair lift
• Fall prevention: High risk due to weakness and postural hypotension

Speech and Language Therapy

• If dysarthria or dysphagia present
• Swallowing assessment (aspiration risk)

Autonomic Management

Drugs to Avoid

Medications that impair neuromuscular transmission can worsen LEMS:

Anesthetic Precautions:

• Inform anesthetist of LEMS diagnosis
• Extreme sensitivity to muscle relaxants (use minimal doses or avoid)
• Risk of post-operative respiratory failure
• Monitor in HDU/ICU post-operatively

---

8. Complications and Prognosis

Complications

Prognosis

Paraneoplastic LEMS

Prognosis determined primarily by underlying SCLC:

Positive Prognostic Factors:

• Limited-stage SCLC at diagnosis
• Good response to chemotherapy
• Younger age
• Good performance status

Non-Paraneoplastic (Autoimmune) LEMS

Generally good prognosis with treatment:

Factors Associated with Better Outcome:

• Early diagnosis and treatment
• Good response to 3,4-DAP
• Younger age
• No comorbidities

Cancer Surveillance

Even after negative initial screening, patients with LEMS require:

• 6-monthly imaging for 2 years
• Annual imaging for up to 5 years
• Clinical vigilance for cancer symptoms

~10% of initially "non-paraneoplastic" cases later develop SCLC. [23]

---

9. Evidence and Guidelines

Key Guidelines

Landmark Evidence

3,4-Diaminopyridine Efficacy

Cochrane Systematic Review (2011): [8]

• Conclusion: 3,4-DAP significantly improves muscle strength and reduces autonomic symptoms in LEMS
• Effect size: Muscle strength score improvement of 3.3 points (95% CI 1.0-5.6)
• Quality of evidence: Moderate (small RCTs but consistent findings)

Key RCTs:

• Sanders et al. (2000): Double-blind RCT, 3,4-DAP vs placebo → significant improvement in weakness and CMAP amplitude [47]
• Oh et al. (2009): 3,4-DAP in LEMS → 62% improvement in compound muscle strength [48]

Immunotherapy

IVIG:

• Bain et al. (1996): IVIG improves strength in LEMS; effect lasts 4-8 weeks [41]

Rituximab:

• Case series: Improvement in refractory LEMS in 50-70% [42]

Cancer Association and Prognosis

Titulaer et al. (2011): [3]

• Large series: 50-60% of LEMS paraneoplastic
• SCLC > 95% of cancer cases
• LEMS associated with limited-stage SCLC and better prognosis

Maddison et al. (2014): [24]

• LEMS patients with SCLC have better cancer outcomes than SCLC without LEMS
• Hypothesis: Immune response against tumor provides anti-tumor effect

---

10. Special Populations

Pregnancy

Rare (LEMS uncommon in women of childbearing age):

Considerations:

• Effect on LEMS: May worsen, remain stable, or improve (variable)
• Neonatal transmission: Transient neonatal LEMS reported (maternal IgG crosses placenta) [49]
• Management:
  • Continue 3,4-DAP if possible (limited safety data; expert opinion suggests acceptable)
  • IVIG safe in pregnancy
  • Avoid azathioprine (teratogenic)
  • "Mycophenolate: Contraindicated (teratogenic)"
  • "Prednisolone: Safe"
• Delivery: Plan with obstetrics and anesthesia (avoid muscle relaxants)

Pediatric LEMS

Extremely rare:

• Usually non-paraneoplastic
• Presentation similar to adults
• Treatment: 3,4-DAP (dose-adjusted for weight), IVIG, corticosteroids [14]

Elderly

Common demographic for paraneoplastic LEMS:

• High SCLC association
• Comorbidities complicate immunotherapy
• Fall risk increased
• Multidisciplinary approach essential

---

11. Patient and Layperson Explanation

What is Lambert-Eaton Myasthenic Syndrome (LEMS)?

LEMS is a rare condition where the body's immune system mistakenly attacks the connections between your nerves and muscles. This makes it hard for nerve signals to reach your muscles, causing weakness, especially in your legs and arms.

What Causes It?

• In about half of people with LEMS, it's linked to a type of lung cancer called small cell lung cancer. The immune system is trying to fight the cancer, but the antibodies also attack the nerve endings.
• In the other half, it's an autoimmune disease, where the immune system attacks your own body without a cancer trigger.

What Are the Symptoms?

• Weakness in your legs and arms: Difficulty standing up from a chair, climbing stairs, or lifting your arms.
• Dry mouth: Very common and can be bothersome.
• Constipation.
• Reduced reflexes: When a doctor taps your knee or ankle with a hammer, the reflex may be weak or absent.
• An unusual feature: Your strength and reflexes may briefly improve after exercising, which is the opposite of most muscle conditions.

How is LEMS Diagnosed?

• Blood tests: Looking for specific antibodies (proteins) that attack the nerve-muscle connections.
• Nerve tests (EMG): A test that checks how well your nerves and muscles work together.
• Scans: Because LEMS can be linked to lung cancer, you will have chest scans (CT or PET scan) to check for cancer.

What is the Treatment?

1. Treating cancer (if present): Chemotherapy and other cancer treatments can improve LEMS symptoms.

2. Medication to improve strength:

   • 3,4-Diaminopyridine (Amifampridine): A medicine that helps your nerves release more signals to your muscles. Most people notice improvement in strength.

3. Immune treatments:

   • IVIG (intravenous immunoglobulin): Given through a drip to calm down the immune system.
   • Steroids: Reduce the immune attack on your nerves.
   • Other immune-suppressing drugs: For long-term control.

4. Supportive care:

   • Physiotherapy to keep muscles strong.
   • Help with walking aids if needed.
   • Treatment for dry mouth (artificial saliva, sipping water).

What is the Outlook?

• If linked to cancer: The outlook depends on the cancer. Treating the cancer often improves the LEMS symptoms.
• If autoimmune (no cancer): With treatment, most people can maintain good strength and quality of life. It's a long-term condition, but manageable with medication.

Important Points

• Cancer screening is essential: Even if the first scans are normal, you'll need regular scans for a few years because cancer can develop later.
• Avoid certain medications: Some antibiotics and anesthetics can make LEMS worse. Always tell your doctor you have LEMS.
• You're not alone: Although rare, there are support groups and specialist centers that understand LEMS.

---

12. Examination Focus (MRCP/Neurology Exams)

High-Yield Exam Topics

1. Antibody Target

Question: "What is the antibody target in LEMS?"

Answer: Presynaptic P/Q-type voltage-gated calcium channels (VGCCs) on the motor nerve terminal. These antibodies reduce calcium influx, impairing acetylcholine release.

2. Malignancy Association

Question: "What cancer is most commonly associated with LEMS?"

Answer: Small Cell Lung Cancer (SCLC) accounts for over 95% of paraneoplastic LEMS cases. Approximately 50-60% of all LEMS is paraneoplastic, and 3% of SCLC patients develop LEMS.

3. Electrophysiology (High-Yield)

Question: "What is the characteristic finding on repetitive nerve stimulation in LEMS?"

Answer: Incremental response (> 100% increase in compound muscle action potential amplitude) with high-frequency stimulation (20-50 Hz) or post-exercise facilitation. This is the opposite of myasthenia gravis (decremental response).

Follow-up: "Why does this occur?"

• At rest, reduced calcium channels → low ACh release → small CMAP.
• With rapid stimulation, calcium accumulates in the terminal → more ACh release → larger CMAP (post-tetanic potentiation).

4. First-Line Symptomatic Treatment

Question: "What is the first-line symptomatic treatment for LEMS?"

Answer: 3,4-Diaminopyridine (Amifampridine)

Mechanism: Blocks presynaptic potassium channels → prolongs depolarization → more calcium influx → increased ACh release.

Dose: 10-20 mg TDS-QDS, maximum 80 mg/day.

Side effects: Perioral tingling, seizures at high doses.

5. Lambert's Sign

Question: "Describe Lambert's sign."

Answer: Post-tetanic potentiation of reflexes. Absent or reduced reflexes (e.g., ankle jerks) transiently reappear or become brisker after 10-15 seconds of sustained muscle contraction (e.g., plantar flexion). This reflects accumulation of calcium in the nerve terminal, temporarily overcoming the VGCC deficiency.

MRCP PACES Scenarios

Scenario 1: Neurology Station - Examine the Legs

Findings:

• Inspection: Normal muscle bulk
• Tone: Normal
• Power: Proximal weakness (hip flexors 4/5, knee extensors 4/5); distal power relatively preserved
• Reflexes: Absent or markedly reduced (especially ankle jerks)
• Sensation: Normal
• Coordination: Normal
• Gait: Proximal weakness → difficulty rising from chair, waddling gait

Key Question: "Can you demonstrate post-tetanic potentiation?"

• Test ankle reflexes → absent
• Ask patient to perform sustained plantar flexion for 10 seconds
• Immediately re-test ankle reflexes → transiently present

Diagnosis: Lambert-Eaton Myasthenic Syndrome

Examiner Questions:

1. "What is the most likely diagnosis?" → LEMS
2. "What would you do next?" → Confirm with anti-VGCC antibodies and RNS; mandatory cancer screening with CT chest
3. "What cancer is associated?" → Small cell lung cancer
4. "How would you treat?" → Treat underlying cancer if present; 3,4-DAP for symptomatic relief; immunotherapy if autoimmune

Scenario 2: History-Taking Station - Weakness

Presenting Complaint: 58-year-old male smoker with 3-month history of difficulty climbing stairs and standing from chairs.

Key History Points to Elicit:

• Weakness pattern: Proximal > distal, legs > arms
• Effect of exercise: Does weakness improve briefly after activity? (Post-tetanic potentiation)
• Autonomic symptoms: Dry mouth (very common), constipation, erectile dysfunction, postural dizziness
• Bulbar symptoms: Diplopia, ptosis (uncommon), dysphagia (uncommon)
• Constitutional symptoms: Weight loss, cough, hemoptysis (cancer symptoms)
• Smoking history: Pack-years
• Autoimmune history: Thyroid disease, vitiligo, other autoimmune conditions

Red Flags:

• Weight loss + smoking → high risk of paraneoplastic SCLC
• Dysphagia/respiratory difficulty → risk of aspiration/respiratory failure

Management Summary:

• Diagnosis: Clinical suspicion + anti-VGCC antibodies + RNS (incremental response)
• Cancer screening mandatory: CT chest (all patients), PET-CT if CT negative and high risk
• Treatment: 3,4-DAP + immunotherapy + treat cancer if present

Viva Questions and Model Answers

Q1: How does LEMS differ from myasthenia gravis?

Answer:

Q2: A patient with LEMS needs surgery. What precautions are required?

Answer:

• Inform anesthetist: LEMS diagnosis
• Muscle relaxants: Patients have extreme sensitivity. Avoid if possible, or use minimal doses with neuromuscular monitoring.
• Post-operative monitoring: Risk of respiratory failure. Monitor in HDU/ICU.
• Medications: Avoid aminoglycosides, magnesium (worsen neuromuscular blockade).
• Continue 3,4-DAP: Peri-operatively if possible.

Q3: Your patient has LEMS and initial CT chest is negative. What next?

Answer:

• Risk stratification:
  • "Check SOX1 antibodies: If positive → very high SCLC risk → proceed to PET-CT"
  • "Calculate DELTA-P score: If ≥3 → high risk → PET-CT"
• PET-CT whole body: Higher sensitivity for occult/small tumors
• If PET-CT negative:
  • "Surveillance: Repeat CT chest every 6 months for 2 years, then annually for up to 5 years"
  • Rationale: Cancer may emerge later in ~10% of initially "non-paraneoplastic" cases
• Classify as autoimmune LEMS: Treat with immunotherapy (IVIG, prednisolone, steroid-sparing agents)

Q4: Explain the mechanism of 3,4-diaminopyridine.

Answer:

• Target: Voltage-gated potassium channels on presynaptic nerve terminal
• Action: Blocks K⁺ channels → prolongs action potential duration
• Effect: Prolonged depolarization → more time for Ca²⁺ influx through the reduced number of VGCCs → increased acetylcholine release
• Result: Improved neuromuscular transmission and muscle strength
• Evidence: Cochrane review shows significant improvement in strength and autonomic symptoms

Q5: What is the DELTA-P score?

Answer: A clinical prediction tool to estimate probability of SCLC in LEMS patients:

• Score ≥3: High probability of SCLC → aggressive screening (PET-CT)
• Sensitivity 89%, specificity 79%

Data Interpretation: RNS Results

Scenario: 60-year-old male with proximal leg weakness and dry mouth. RNS performed on abductor digiti minimi:

Question: Interpret the findings.

Answer:

• Resting CMAP: 2.0 mV (reduced; normal ~10 mV) → baseline impaired neuromuscular transmission
• Low-frequency stimulation: 15% decrement → further reduction with repetitive low-frequency stimulation
• Post-exercise facilitation: 6.5 mV (225% increase from resting)
• Interpretation: Incremental response > 100% → diagnostic of Lambert-Eaton Myasthenic Syndrome
• Next steps: Anti-VGCC antibodies to confirm; mandatory cancer screening (CT chest, consider PET-CT)

---

13. References

Primary Sources

1. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107. PMID: 22094130. DOI: 10.1016/S1474-4422(11)70245-9.

2. Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton Myasthenic Syndrome. Neurol Clin. 2018;36(2):379-394. PMID: 29655456. DOI: 10.1016/j.ncl.2018.01.008.

3. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-908. PMID: 21282539. DOI: 10.1200/JCO.2010.32.0440.

4. Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of FDA and EMA-approved pyridostigmine in Lambert-Eaton myasthenic syndrome: a randomised, double-blind, placebo-controlled, crossover study. Lancet Neurol. 2009;8(12):1083-1091. PMID: 19909910. DOI: 10.1016/S1474-4422(09)70224-9.

5. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt 3):577-596. PMID: 2838124. DOI: 10.1093/brain/111.3.577.

6. Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005;32(4):515-520. PMID: 15962333. DOI: 10.1002/mus.20389.

7. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000;54(11):2176-2178. PMID: 10851384. DOI: 10.1212/wnl.54.11.2176.

8. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;(2):CD003279. PMID: 21328259. DOI: 10.1002/14651858.CD003279.pub3.

9. Verschuuren JJ, Wirtz PW, Titulaer MJ, Willems LN, van Gerven J. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother. 2006;7(10):1323-1336. PMID: 16805717. DOI: 10.1517/14656566.7.10.1323.

10. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359-363. PMID: 12140106. DOI: 10.1016/s0303-8467(02)00054-9.

11. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2002;73(6):766-768. PMID: 12438496. DOI: 10.1136/jnnp.73.6.766.

12. Mareska M, Gutmann L. Lambert-Eaton myasthenic syndrome. Semin Neurol. 2004;24(2):149-153. PMID: 15257511. DOI: 10.1055/s-2004-829587.

13. Lorenzoni PJ, Scola RH, Kay CS, et al. Lambert-Eaton myasthenic syndrome: a study of 20 Brazilian patients. Arq Neuropsiquiatr. 2010;68(6):849-854. PMID: 21243242. DOI: 10.1590/s0004-282x2010000600004.

14. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58(1):85-87. PMID: 7823075. DOI: 10.1136/jnnp.58.1.85.

15. Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology. 2002;59(11):1773-1775. PMID: 12473767. DOI: 10.1212/01.wnl.0000037481.33780.4b.

16. Takamori M. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis. J Neuroimmunol. 2008;201-202:145-152. PMID: 18653246. DOI: 10.1016/j.jneuroim.2008.06.003.

17. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353(9147):117-118. PMID: 10023899. DOI: 10.1016/S0140-6736(05)76153-5.

18. Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry. 1991;54(9):764-767. PMID: 1660924. DOI: 10.1136/jnnp.54.9.764.

19. Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924-928. PMID: 18032744. DOI: 10.1212/01.wnl.0000281663.81079.24.

20. Willcox N, Demaine AG, Newsom-Davis J, Welsh KI, Robb SA, Spiro SG. Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Hum Immunol. 1985;14(3):29-36. PMID: 2997080. DOI: 10.1016/0198-8859(85)90214-x.

21. Maddison P, Newsom-Davis J. Lambert-Eaton myasthenic syndrome: clinical and electrophysiological evidence for a humoral factor. Muscle Nerve (Suppl). 2000;9:S203-S208. PMID: 11135266.

22. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature. 1985;317(6039):737-739. PMID: 2997619. DOI: 10.1038/317737a0.

23. Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry. 2001;70(2):212-217. PMID: 11160470. DOI: 10.1136/jnnp.70.2.212.

24. Maddison P, Gozzard P, Grainge MJ, Lang B. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2017;88(14):1334-1339. PMID: 28275083. DOI: 10.1212/WNL.0000000000003794.

25. Takamori M, Komai K, Iwasa K. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am J Med Sci. 2000;319(4):204-208. PMID: 10768604. DOI: 10.1097/00000441-200004000-00002.

26. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA. 1983;80(24):7636-7640. PMID: 6324182. DOI: 10.1073/pnas.80.24.7636.

27. Verschuuren J, Dalmau J, Hoard R, Posner JB. Paraneoplastic anti-Hu serum: studies on human tumors and cultured neurons. J Neuroimmunol. 1997;75(1-2):200-204. PMID: 9143254. DOI: 10.1016/s0165-5728(97)00025-9.

28. Sanders DB, Stalberg EV. AAEM minimonograph #25: single-fiber electromyography. Muscle Nerve. 1996;19(9):1069-1083. PMID: 8761262. DOI: 10.1002/(SICI)1097-4598(199609)19:9less than 1069::AID-MUS1> 3.0.CO;2-6.

29. O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology. 1998;50(1):88-93. PMID: 9443463. DOI: 10.1212/wnl.50.1.88.

30. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990;40(10):1552-1556. PMID: 2170871. DOI: 10.1212/wnl.40.10.1552.

31. Gutmann L, Phillips LH 2nd, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology. 1992;42(4):848-850. PMID: 1314350. DOI: 10.1212/wnl.42.4.848.

32. Newsom-Davis J. A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci. 2003;998:217-222. PMID: 14592878. DOI: 10.1196/annals.1254.023.

33. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984;34(4):480-485. PMID: 6322050. DOI: 10.1212/wnl.34.4.480.

34. Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005;32(4):515-520. PMID: 15962333. DOI: 10.1002/mus.20389.

35. Maddison P, Newsom-Davis J, Mills KR. Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1998;65(4):213-217. PMID: 9703172. DOI: 10.1136/jnnp.65.2.213.

36. Altman AJ, Baehring JM. Paraneoplastic syndromes of the nervous system in children. Pediatr Blood Cancer. 2006;46(3):273-278. PMID: 16333825. DOI: 10.1002/pbc.20614.

37. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140. PMID: 15258215. DOI: 10.1136/jnnp.2003.034447.

38. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-908. PMID: 21282539. DOI: 10.1200/JCO.2010.32.0440.

39. Lundh H, Nilsson O, Rosén I. Effects of 3,4-diaminopyridine and 4-aminopyridine on neuromuscular transmission in a patient with Lambert-Eaton syndrome. J Neurol Neurosurg Psychiatry. 1983;46(7):654-662. PMID: 6310021. DOI: 10.1136/jnnp.46.7.654.

40. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990;40(10):1552-1556. PMID: 2170871. DOI: 10.1212/wnl.40.10.1552.

41. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678-683. PMID: 8797464. DOI: 10.1212/wnl.47.3.678.

42. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671-673. PMID: 21386110. DOI: 10.1136/jnnp.2009.197632.

43. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-4544. PMID: 17008692. DOI: 10.1200/JCO.2005.04.4859.

44. Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry. 2001;70(2):212-217. PMID: 11160470. DOI: 10.1136/jnnp.70.2.212.

45. Jacob S, Viegas S, Leite MI, et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol. 2012;69(8):994-1001. PMID: 22490322. DOI: 10.1001/archneurol.2012.437.

46. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-425. PMID: 27358333. DOI: 10.1212/WNL.0000000000002790.

47. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54(3):603-607. PMID: 10680791. DOI: 10.1212/wnl.54.3.603.

48. Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 2009;40(5):795-800. PMID: 19670726. DOI: 10.1002/mus.21422.

49. Newsom-Davis J, Lachmann HJ, Lecky B, et al. Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients. J Neurol Neurosurg Psychiatry. 1991;54(5):452-453. PMID: 1865209. DOI: 10.1136/jnnp.54.5.452.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists for complex neuromuscular disorders and paraneoplastic syndromes.